Clinical trials: SCLC, Extensive Stage
Lung Cancer
BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BBR 3464 in treating patients who have metastatic small…
- Trial name
- NCT00014547
- Testing
- BBR 3464
- Where
- 18 sites in United States
- Sponsor
- Theradex
Extensive-stage Small-cell Lung Cancer
Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
This is a prospective observational clinical study designed to predict the therapeutic efficacy of first-line treatment with tislelizumab combined with standard chemotherapy in patients with ES-SCLC using TCR repertoire…
- Trial name
- ES-SCLC (NCT07244016)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer, Small Cell Lung Cancer
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
This trial is titled "A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC)." Part 1, the phase 1b portion of this study, is a…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- SCLC (NCT00791154)
- Testing
- AMG 479, Etoposide, AMG 102
- Volunteers
- 213 people
- Sponsor
- NantCell, Inc.
Small Cell Lung Carcinoma
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
This single-arm, Phase II study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) combination with Apatinib in participants with ES-SCLC who was response or stable…
- Trial name
- CAMERA (NCT04901754)
- Testing
- Camrelizumab Plus Apatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Henan Cancer Hospital
SCLC,Extensive Stage
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
- Trial name
- THOR (NCT05623319)
- Testing
- Pembrolizumab/Olaparib
- Where
- 12 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Extensive Stage Lung Small Cell Carcinoma
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the…
- Trial name
- NCT04402788
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 411 sites in United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Comparison of two combination chemotherapies in the treatment of patients with SLCL
- Trial name
- NCT00168896
- Testing
- Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
- Where
- Germany
- Volunteers
- 286 people
- Sponsor
- Charite University, Berlin, Germany
Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer
Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer
Lung cancer remains a leading cause of cancer-related deaths worldwide, with small cell lung cancer (SCLC) accounting for 15-20% of all lung cancers.
- Conditions
- Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer, ECOG Performance Status Score of 0 or 1, Expected Survival ≥3 Months
- Trial name
- NCT06554535
- Testing
- Serplulimab，Platinum-based Chemotherapy，Aspirin
- Volunteers
- 43 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib…
- Trial name
- NCT07358676
- Testing
- Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer Extensive Stage
Liposomal Irinotecan and Apatinib in ES-SCLC
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
- Trial name
- LIAES (NCT06749691)
- Testing
- Liposomal Irinotecan and Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
This is an open-label, randomized, multi-cohort, multi-center, phase Ib/II study to evaluate the safety and efficacy of Adebrelimab plus Irinotecan Liposome (II) with or without Famitinib in patients with extensive-stage small…
- Trial name
- NCT06332950
- Testing
- Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Baohui Han
Small Cell Lung Cancer Extensive Stage
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the…
- Trial name
- NCT04967625
- Testing
- Sintilimab, Anlotinib hydrochloride
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites.
- Trial name
- NCT07895043
- Testing
- Alveltamig, Atezolizumab, ABBV-706
- Volunteers
- 80 people
- Sponsor
- AbbVie
Small-cell Lung Cancer
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT04923776
- Testing
- Carboplatin, Etoposide, Atezolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brian Henick, MD
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00004055
- Testing
- filgrastim, paclitaxel, topotecan hydrochloride
- Where
- 19 sites in United States
- Volunteers
- 38 people
- Sponsor
- Alliance for Clinical Trials in Oncology
SCLC, Extensive Stage
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
This is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib…
- Trial name
- Aurora 005 (NCT07538271)
- Testing
- benmelstobart, Anlotinib, Carboplatin or cisplatin
- Volunteers
- 33 people
- Sponsor
- Yayi He
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment).
- Conditions
- Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
- Trial name
- NCT05068232
- Testing
- Ablative Radiation, Durvalumab, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Chicago
Extensive Stage Small Cell Lung Cancer
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may make tumor cells more sensitive to chemotherapy drugs.
- Trial name
- NCT00017251
- Testing
- oblimersen sodium, carboplatin, etoposide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Cancer
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
START-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable…
- Trial name
- START-lung (NCT07203053)
- Testing
- Tarlatamab
- Where
- 19 sites in France, Greece and 3 more
- Volunteers
- 48 people
- Sponsor
- ETOP IBCSG Partners Foundation